124 related articles for article (PubMed ID: 34707089)
1. The effects of STA-9090 (Ganetespib) and venetoclax (ABT-199) combination on apoptotic pathways in human cervical cancer cells.
Karademir D; Özgür A
Med Oncol; 2023 Jul; 40(8):234. PubMed ID: 37432531
[TBL] [Abstract][Full Text] [Related]
2. The BCL2 inhibitor venetoclax mediates anticancer effects through dendritic cell activation.
Liu P; Zhao L; Zitvogel L; Kepp O; Kroemer G
Cell Death Differ; 2023 Dec; 30(12):2447-2451. PubMed ID: 37845384
[TBL] [Abstract][Full Text] [Related]
3. Getting more bang for their buck: BCL2 inhibitors boost dendritic-cell function to enhance anti-cancer immune surveillance.
Montes-Gómez AE; Tait SWG
J Transl Med; 2024 Mar; 22(1):317. PubMed ID: 38549077
[TBL] [Abstract][Full Text] [Related]
4. Venetoclax induces BCL-2-dependent Treg to TH17 plasticity to enhance the antitumor efficacy of anti-PD-1 checkpoint blockade.
Liao R; Hsu JY; Aboelella NS; McKeever JA; Thomas-Toth AT; Koh AS; LaBelle JL
Cancer Immunol Res; 2024 May; ():. PubMed ID: 38810242
[TBL] [Abstract][Full Text] [Related]
5. Steroid-free combination of 5-azacytidine and venetoclax for the treatment of multiple myeloma.
Flanagan L; Coughlan A; Cosgrove N; Roe A; Wang Y; Gilmore S; Drozdz I; Comerford C; Ryan J; Minihane E; Parvin S; O'Dwyer M; Quinn J; Murphy P; Furney S; Glavey S; Chonghaile TN; ; ;
Haematologica; 2024 Mar; ():. PubMed ID: 38511268
[TBL] [Abstract][Full Text] [Related]
6. Lee JB, Khan DH, Hurren R, et al. Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production. Blood. 2021;138(3):234-245.
Blood; 2023 Mar; 141(12):1495. PubMed ID: 36951880
[No Abstract] [Full Text] [Related]
7. Respiratory complex I regulates dendritic cell maturation in explant model of human tumor immune microenvironment.
Turpin R; Liu R; Munne PM; Peura A; Rannikko JH; Philips G; Boeckx B; Salmelin N; Hurskainen E; Suleymanova I; Aung J; Vuorinen EM; Lehtinen L; Mutka M; Kovanen PE; Niinikoski L; Meretoja TJ; Mattson J; Mustjoki S; Saavalainen P; Goga A; Lambrechts D; Pouwels J; Hollmén M; Klefström J
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604809
[TBL] [Abstract][Full Text] [Related]
8. Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study.
Al-Sawaf O; Zhang C; Lu T; Liao MZ; Panchal A; Robrecht S; Ching T; Tandon M; Fink AM; Tausch E; Schneider C; Ritgen M; Böttcher S; Kreuzer KA; Chyla B; Miles D; Wendtner CM; Eichhorst B; Stilgenbauer S; Jiang Y; Hallek M; Fischer K
J Clin Oncol; 2021 Dec; 39(36):4049-4060. PubMed ID: 34709929
[TBL] [Abstract][Full Text] [Related]
9. AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill
Post SM; Ma H; Malaney P; Zhang X; Aitken MJL; Mak PY; Ruvolo VR; Yasuhiro T; Kozaki R; Chan LE; Ostermann LB; Konopleva M; Carter BZ; DiNardo C; Andreeff MD; Khoury JD; Ruvolo PP
Haematologica; 2022 Jun; 107(6):1311-1322. PubMed ID: 34732043
[TBL] [Abstract][Full Text] [Related]
10. Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance.
Liu F; Zhao Q; Su Y; Lv J; Gai Y; Liu S; Lin H; Wang Y; Wang G
Exp Hematol; 2022 Jan; 105():39-49. PubMed ID: 34767916
[TBL] [Abstract][Full Text] [Related]
11. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.
Wang M; Ramchandren R; Chen R; Karlin L; Chong G; Jurczak W; Wu KL; Bishton M; Collins GP; Eliadis P; Peyrade F; Lee Y; Eckert K; Neuenburg JK; Tam CS
J Hematol Oncol; 2021 Oct; 14(1):179. PubMed ID: 34717692
[TBL] [Abstract][Full Text] [Related]
12. Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management.
Eyre TA; Hori S; Munir T
Hematol Oncol; 2022 Apr; 40(2):129-159. PubMed ID: 34713475
[TBL] [Abstract][Full Text] [Related]
13. Innovations in conditioning and post-transplant maintenance in AML: genomically informed revelations on the graft-versus-leukemia effect.
Murdock HM; Ho VT; Garcia JS
Front Immunol; 2024; 15():1359113. PubMed ID: 38571944
[TBL] [Abstract][Full Text] [Related]
14. Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment.
Hänel G; Schönle A; Neumann AS; Nixdorf D; Philipp N; Sponheimer M; Leutbecher A; Emhardt AJ; Magno G; Bücklein V; Eckmann J; Dunshee D; Kramar V; Korfi K; Colombetti S; Umaña P; Klein C; Subklewe M
Leukemia; 2024 Feb; 38(2):398-402. PubMed ID: 38212534
[No Abstract] [Full Text] [Related]
15. Targeted Polymersome Delivery of a Stapled Peptide for Drugging the Tumor Protein p53:BCL-2-Family Axis in Diffuse Large B-Cell Lymphoma.
Schnorenberg MR; Hawley KM; Thomas-Toth AT; Watkins EA; Tian Y; Ting JM; Leak LB; Kucera IM; Raczy MM; Kung AL; Hubbell JA; Tirrell MV; LaBelle JL
ACS Nano; 2023 Dec; 17(23):23374-23390. PubMed ID: 37688780
[TBL] [Abstract][Full Text] [Related]
16. Selective Bcl-2 inhibition promotes hematopoietic chimerism and allograft tolerance without myelosuppression in nonhuman primates.
Sasaki H; Hirose T; Oura T; Otsuka R; Rosales I; Ma D; Lassiter G; Karadagi A; Tomosugi T; Dehnadi A; Matsunami M; Raju Paul S; Reeves PM; Hanekamp I; Schwartz S; Colvin RB; Lee H; Spitzer TR; Cosimi AB; Cippà PE; Fehr T; Kawai T
Sci Transl Med; 2023 Apr; 15(690):eadd5318. PubMed ID: 37018417
[TBL] [Abstract][Full Text] [Related]
17. Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells.
Teh CE; Peng H; Luo MX; Tan T; Trussart M; Howson LJ; Chua CC; Muttiah C; Brown F; Ritchie ME; Wei AH; Roberts AW; Bryant VL; Anderson MA; Lindeman GJ; Huang DCS; Thijssen R; Gray DHD
Blood Adv; 2023 Jun; 7(12):2733-2745. PubMed ID: 36521105
[TBL] [Abstract][Full Text] [Related]
18. Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination.
Lew TE; Seymour JF
J Hematol Oncol; 2022 Jun; 15(1):75. PubMed ID: 35659041
[TBL] [Abstract][Full Text] [Related]
19. Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells.
Ludwig LM; Hawley KM; Banks DB; Thomas-Toth AT; Blazar BR; McNerney ME; Leverson JD; LaBelle JL
Cell Death Dis; 2021 Oct; 12(11):1005. PubMed ID: 34707089
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
